According to information, on Monday, Moderna (MRNA.US) shares surged, rising over 7% to $27.85 by the time of reporting. The company presented the latest data from its mRNA vaccine pipeline at the IDWeek 2025 conference, including clinical results for the seasonal flu vaccine mRNA-1010 and the combination vaccine mRNA-1018. The data showed that both vaccines elicited rapid and robust immune responses in adult subjects, with no significant safety issues observed.